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Irinotecan and its metabolite SN38 
inhibits procollagen I production 
of dermal fibroblasts from Systemic 
Sclerosis patients
J. Lapoirie1, L. Tran2, L. Piazza3, C. Contin‑Bordes4, M. E. Truchetet4,5 & F. Bonnet1,6*
Systemic sclerosis (SSc) is a rare autoimmune connective tissue disease characterized by a 
microangiopathy and fibrosis of the skin and internal organs. No treatment has been proved to be 
efficient in case of early or advanced SSc to prevent or reduce fibrosis. There are strong arguments 
for a key role of topo‑I in the pathogenesis of diffuse SSc. Irinotecan, a semisynthetic derivative 
of Camptothecin, specifically target topo‑I. This study was undertaken to evaluate the effects 
of noncytotoxic doses of irinotecan or its active metabolite SN38 on collagen production in SSc 
fibroblasts. Dermal fibroblasts from 4 patients with SSc and 2 healthy donors were cultured in the 
presence or absence of irinotecan or SN38. Procollagen I release was determined by ELISA and 
expression of a panel of genes involved in fibrosis was evaluated by qRT‑PCR. Subcytotoxic doses of 
irinotecan and SN38 caused a significant and dose‑dependent decrease of the procollagen I production 
in dermal fibroblasts from SSc patients, respectively − 48 ± 3%, p < 0.0001 and − 37 ± 6.2%, p = 0.0097. 
Both irinotecan and SN38 led to a global downregulation of genes involved in fibrosis such as COL1A1, 
COL1A2, MMP1 and ACTA2 in dermal fibroblasts from SSc patients (respectively − 27; − 20.5; − 30.2 
and − 30% for irinotecan and − 61; − 55; − 50 and − 54% for SN38). SN38 increased significantly CCL2 
mRNA level (+ 163%). The inhibitory effect of irinotecan and its active metabolite SN38 on collagen 
production by SSc fibroblasts, which occurs through regulating the levels of expression of genes 
mRNA, suggests that topoisomerase I inhibitors may be effective in limiting fibrosis in such patients.
Abbreviations
Topo-I  Anti-topoisomerase I
ECM  Extracellular matrix
FBS  Foetal bovine serum
HD  Healthy donors
HSCT  Hematopoietic stem cell transplantation
PBMC  Peripheral blood mononuclear cells
SSc  Systemic sclerosis
Systemic sclerosis (SSc) is a multisystem connective tissue disorder featured by vascular injury, autoimmune 
background and fibrosis affecting the skin and internal organs. The pathophysiology of SSc remains incompletely 
understood but involves a complex network of interactions between the microvascular system, activation of 
autoimmune processes, and chronic activation of fibroblasts leading to the deregulated production of extracel-
lular matrix (ECM) proteins, predominantly type I collagen, and finally fibrosis 1,2.
There is no specific therapeutic for SSc. The use of immunosuppressive agents is frequent in case of extensive 
skin or visceral involvement, in particular cyclophosphamide, mycophenolate mofetil and methotrexate. In 
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the last few years, many treatments have been evaluated in SSc : targeted immunotherapies such as belimumab 
3, pomalidomide 4 or tocilizumab 5; anti-fibrotic therapies such as pirfenidone 6 and nintedanib 7 which are 
approved for use in patients with idiopathic pulmonary fibrosis 8 and riociguat 9 which is approved in pulmonary 
arterial hypertension 10 for its vascular benefit. Neither of these treatments has been shown to have a benefit on 
overall and respiratory mortality, or on skin and lung fibrosis compared to placebo, except a small but significant 
effect on full vital capacity of nintedanib.
An international consortium implemented a therapeutic trial evaluating autologous hematopoietic stem 
cell transplantation (HSCT) versus intravenous pulse cyclophosphamide in diffuse cutaneous SSc 11. Patients in 
the HSCT group experienced better long-term overall survival but higher mortality in the first year than those 
treated with cyclophosphamide alone.
Thus, treatment for fibrosis in SSc is still an unmet medical need.
Anti-topoisomerase I (Topo-I) antibodies are frequently associated to diffuse cutaneous SSc and to severe 
systemic and visceral involvement (pulmonary fibrosis, cardiac, digestive and joint involvement, scleroderma 
renal crisis) 12. Human DNA topo-I is a 765-amino-acid nuclear enzyme involved in topological changes of DNA 
structure. It plays key roles in alleviating the topological stresses that arise during DNA replication and transcrip-
tion by nicking, relaxing, and re-ligating the double-stranded DNA structure. There are strong arguments for 
a key role of topo-I in the pathogenesis of scleroderma since topo-I is overexpressed in SSc 13. Indeed, selective 
oxidation of DNA topo-I induces SSc in the mouse and is associated with anti-topo-I antibodies occurrence, 
endothelial production of reactive oxygen species and fibroblast hyperproliferation, showing that the specific 
oxidation of topo-I directly participates in the pathogenesis of SSc 14. Moreover, topo-I is able to bind specifically 
to the cell surface of fibroblasts 15 and then induce anti–topo-I autoantibodies binding, trigger the adhesion and 
activation of monocytes 16 and activate T-lymphocytes 17. These cells could further lead to the initiation and 
maintenance of an inflammatory cascade, stimulating the fibrosis that is characteristic of SSc.
Irinotecan, a semisynthetic derivative of the natural alkaloid Camptothecin, specifically target topo-I. The 
conversion of the water-soluble irinotecan prodrug into its active metabolite SN38 allows DNA cleavage but 
inhibits subsequent ligation by trapping the enzyme on DNA, generating cytotoxic protein-linked DNA breaks 
18,19. Irinotecan is currently a major anticancer drug, contributing to the treatment of patients with advanced 
colon cancers and other solid tumors including non-small cell lung cancer, pancreatic and biliary tract cancers, 
advanced gastric and cervical cancer 20–23.
We observed surprisingly that irinotecan or an irinotecan active metabolite administered in a patient suffering 
from both rectum adenocarcinoma and SSc with anti topo-I antibodies to high level (141 IU/mL, normal range 
0–29) can improve fibrosis, and in particular skin involvement (personal data).
Regarding our case report and the analysis of the literature, we hypothesize that irinotecan or its active 
metabolite SN38 may have an effect on the inhibition of the production of collagen by SSc fibroblasts and could 
represent a specific treatment for diffuse SSc. The aim of this study was to evaluate the effect of subcytotoxic doses 
of irinotecan and SN38 on collagen production by dermal fibroblasts obtained from patients with diffuse SSc.
Methods
Study population. The subjects were patients with diffuse cutaneous SSc and healthy volunteers. Patients 
with diffuse SSc were included in the context of the VISS (Vasculopathy and Inflammation in Systemic Sclerosis) 
biomedical research project funded in 2012 and approved by the institutional ethical committee of Bordeaux 
University Hospital (CPP, 2012-A00081-42). Informed consent was obtained from all participants and research 
have been performed in accordance with the Declaration of Helsinki. All participants satisfied the classification 
criteria proposed by the American College of Rheumatology (ACR) and the European League Against Rheuma-
tism (EULAR) 2013 24 and suffered from diffuse SSc with positive anti topo-I antibodies. Punch biopsy specimen 
of affected mid-forearm skin were obtained. The control group were healthy donors (HD) that underwent plastic 
surgery (brachioplasty). None of the healthy individuals had dermatological disorders or were under immuno-
suppressive agents/glucocorticoids.
Cell culture. Fibroblasts were obtained from skin lesion biopsy samples from 2 HD and 4 SSc patients. Skin 
biopsies were digested with 0.1% type Ia collagenase at 37 °C for 2-h. Adherent cells were grown in DMEM 
medium containing 2 mM of L-glutamine, 50 U/mL penicillin, 50 µg/ml streptomycin and 10% foetal bovine 
serum (FBS) (cDMEM). To keep homogeneity between fibroblasts they were used between the third and sixth 
passages 25.
Determination of procollagen I release. Dermal fibroblasts were monolayer plated at 20,000 cell per 
well in DMEM 10% FBS supplemented with 20 µg/mL of vitamin C in 96-well plates. 24 h before the experiment, 
medium was switched to DMEM 0% FBS supplemented with 20 µg/mL of vitamin C (L-Ascorbic acid). As dem-
onstrated in the literature,  IC50 inhibition of proliferation values for irinotecan were between 2 and 3.8 µM 26, the 
first concentration producing significant cytotoxicity being 32 µM 27, whereas  IC50 values for SN38 were 0.1 µM 
28. In consequence, cells were treated for 48 h with irinotecan (0.006, 0.6, 6 or 40 µg/mL, corresponding to 0.01, 
0.1, 1 or 64 µM) or SN38 (0.01, 0.06, 0.1 or 0.3 µg/mL, corresponding to 0.025, 0.15, 0.25 or 0.76 µM) in DMEM 
1% FBS supplemented with 20 µg/mL of vitamin C. Supernatants were collected to evaluate the procollagen I 
release level by ELISA kit (ref MK101, supplier Takara) according to the manufacturer’s instructions. Each reac-
tion was performed in triplicate. The level of procollagen I release was presented as fold change compared with 
the procollagen I release by the same non-treated fibroblasts arbitrary fixed at 100%.
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Quantitative real‑time PCR. Dermal fibroblasts were plated in DMEM 10% FCS in 24-well plates. 24 h 
before the experiment, medium was switched to DMEM 0% FBS. Cells were treated for 24 h with irinotecan (2 
or 20 µg/mL, corresponding to 3.2 µM or 32 µM) or SN38 (0.04 or 0.4 µg/mL, corresponding to 0.1 or 1 µM) in 
DMEM 1% FBS. Supernatants were removed and plates were freezed at − 80°c. Total fibroblasts RNA from each 
well-plate were extracted with NucleoSpin® RNA Plus kit (Macherey–Nagel) according to the manufacturer’s 
instructions. The quantity and quality of RNA were evaluated by capillary electrophoresis (Bioanalyzer 2100, 
Agilent). RNA was used for cDNA synthesis using the Transcriptor Reverse Transcriptase kit (Roche). qPCR 
reactions were run on a Light Cycler (Roche Molecular Systems Inc.) according to the manufacturer’s instruc-
tions. The specific primer pairs for each gene are described in the supplementary material table 1. Each reaction 
was performed in triplicate. The relative gene expression levels of COL1A1, COL1A2, MMP1, TIMP1, CCL2 and 
ACTA2 were calculated using the ΔΔCt method. Target mRNA levels were normalized to stable housekeeping 
gene GAPDH (Glyceraldehyde-3-phsophate dehydrogenase). Expression of the genes in the different treated 
conditions was presented as fold change compared with the gene expression of the same non-treated fibroblasts 
arbitrary fixed at 100%.
Statistical analysis. Statistical analyses were performed using GraphPad Prism (La Jolla, CA). Statistical 
significance was evaluated using paired t-test. Data values are expressed as means ± SEM. A p-value < 0.05 was 
considered statistically significant.
Ethics approval and consent to participate. The VISS (Vasculopathy and Inflammation in Systemic 
Sclerosis) biomedical research project has been approved by the institutional ethical committee (CPP, 2012-
A00081-42). All participants provided written informed consent before inclusion.
Results
Irinotecan decreases procollagen I production of dermal fibroblasts in a dose‑dependent 
manner. The main manifestation of systemic sclerosis is the overproduction of ECM and especially type 
I collagen. Therefore, we assessed whether irinotecan directly impacts the procollagen I production of dermal 
fibroblasts. Four concentrations of irinotecan (0.006 µg/ml, 0.6 µg/ml, 6 µg/ml, 40 µg/ml) were assessed and 
compared to a non-treated condition. All the doses used were under a cytotoxic threshold determined on fibro-
blasts by preliminary toxic analysis at concentration of irinotecan of 200 µg/ml (supplementary data tables 2a). 
Irinotecan treatment during 48 h resulted in a dose-dependent decrease of procollagen I production levels in 
SSc and HD fibroblasts. In a representative experiment, the highest dose of irinotecan (40 µg/mL) resulted in 
about 45% inhibition of procollagen I production levels in SSc fibroblasts (Fig. 1A). The effect of irinotecan at 
the concentration of 40 µg/mL on the release of procollagen I protein was then assessed in 4 SSc patients and 2 
HD dermal fibroblasts. Three independent experiments were done. Incubation with 40 µg/mL irinotecan during 
48 h significantly decreased the release of procollagen I protein in SSc patients (− 48.5 ± 3 for dermal fibroblasts 
of SSc patients treated with irinotecan vs. the non-treated condition, Fig. 1B  p <  0.0001, paired t-test). No differ-
ence was noted between SSc patients and HD dermal fibroblasts (data not shown).














































Figure 1.  Analysis of irinotecan effect on procollagen I release of dermal SSc fibroblasts. The level of 
procollagen I release was evaluated after 48 h in dermal fibroblasts from SSc patients incubated with irinotecan. 
A comparison of procollagen I release level was done between non-treated condition and treated conditions. (A) 
Data from a representative experiment showing a dose-dependent effect on the procollagen I production of SSc 
fibroblasts after incubation with 4 different doses of irinotecan (i.e. 0.006 µg/ml, 0.6 µg/ml, 6 µg/ml, 40 µg/ml). 
(B) Cumulative data from 3 independent experiments showing a decrease of procollagen I production in SSc 
fibroblasts incubated with irinotecan (40 µg/ml). ****p < 0.0001 using paired t-test.
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SN38 decreases procollagen I production of dermal fibroblasts in a dose‑dependent man‑
ner. We assessed whether an irinotecan active metabolite, SN38, directly impacts the procollagen I produc-
tion of dermal fibroblasts. Four concentrations of SN38 (0.01, 0.06, 0.1 or 0.3 µg/mL), were assessed and com-
pared to a non-treated condition. All the doses used were under a cytotoxic threshold determined on fibroblasts 
by preliminary toxic analysis at concentration of SN38 of 1 µg/ml (2.55 µM) (supplementary data tables 2b). 
SN38 treatment during 48 h resulted in a dose-dependent decrease of procollagen I production levels in SSc 
and HD fibroblasts. In a representative experiment, the highest dose of SN38 (0.3 µg/mL) resulted in about 50% 
inhibition of procollagen I production levels in SSc fibroblasts (Fig. 2A). The effect of SN38 at the concentration 
of 0.3 µg/mL on the release of procollagen I protein was then assessed in 4 SSc patients and 2 HD dermal fibro-
blasts. Three independent experiments were done. Incubation with 0.3 µg/mL SN38 during 48 h significantly 
decreased the release of procollagen I protein in SSc patients (− 37 ± 6.2 for dermal fibroblasts of SSc patients 
treated with SN38 vs. the non-treated condition, Fig.  2B  p = 0.0097, paired t-test). No difference was noted 
between SSc patients and HD dermal fibroblasts (data not shown).
Subcytotoxic doses of irinotecan decrease mRNA expression of a panel of genes involved in 
fibrosis. To assess the effect of irinotecan on mRNA levels of a panel of gene related to fibrosis, 4 SSc patients 
and 2 HD dermal fibroblasts were incubated with or without irinotecan during 24 h. As reported before, the 
two concentrations (2 µg/mL and 20 µg/mL) of irinotecan used were not cytotoxic on the fibroblasts and led 
to a global downregulation of genes involved in fibrosis in SSc patients, except for the metallopeptidase inhibi-
tor TIMP1 gene (supplementary data Fig. 1). Incubation with the highest evaluated dose of irinotecan (20 µg/
mL) during 24 h significantly decreased mRNA expression of MMP1 (− 30.25 ± 11, p = 0.05, paired t-test) and 
ACTA2 (− 30 ± 5.4, p = 0.0117, paired t-test) in dermal fibroblasts of SSc patients treated with irinotecan vs. the 
non-treated condition. Although incubation with 20 µg/mL irinotecan during 24 h decreased mRNA expres-
sion of COL1A1 (− 27 ± 13.25), COL1A2 (− 20.5 ± 9) and CCL2 (− 15 ± 9.4) in dermal fibroblasts of SSc patients 
treated with irinotecan vs. the non-treated condition, these differences were not statistically significant (Fig. 3). 
Finally, irinotecan had no effect on mRNA expression of TIMP1 (− 4.5 ± 9.6). No difference was noted between 
SSc patients and HD dermal fibroblasts (data not shown).
Subcytotoxic doses of SN38 decrease mRNA expression of a panel of genes involved in fibro‑
sis. To assess the effect of SN38, an active irinotecan metabolite, on mRNA levels of a panel of fibrosis gene, 
4 SSc patients and 2 HD dermal fibroblasts were incubated with or without SN38 during 24 h. As reported 
before, the two concentrations (0.04 µg/mL and 0.4 µg/mL) of SN38 used were not cytotoxic on the fibroblasts 
and led to a global downregulation of genes involved in fibrosis in SSc patients (supplementary data Fig. 1), 
except for TIMP1 and CCL2 genes (supplementary data Fig. 2). Incubation with the highest evaluated dose of 
SN38 (0.4 µg/mL) during 24 h significantly decreased mRNA expression of COL1A1 (− 61.75 ± 5.8, p = 0.0018, 
paired t-test), COL1A2 (− 55.75 ± 3.7, p = 0.0007, paired t-test), MMP1 (− 50.75 ± 8,1, p = 0.0084, paired t-test) 
and ACTA2 (− 54.25 ± 7.6, p = 0.0057, paired t-test) in dermal fibroblasts of SSc patients treated with SN38 vs. 
the non-treated condition (Fig. 4). SN38 had no effect on mRNA expression of TIMP1 (− 6 ± 9.4). In contrast, 




















































Figure 2.  Analysis of SN38 effect on procollagen I release of dermal SSc fibroblasts. The level of procollagen 
I release was evaluated after 48 h in dermal fibroblasts from SSc patients incubated with SN38. A comparison 
of procollagen I release level was done between non-treated condition and treated conditions. (A) Data 
from a representative experiment showing a dose-dependent effect on the procollagen I production of SSc 
fibroblasts after incubation with 4 different doses of SN38 (i.e. 0.01 µg/ml, 0.06 µg/ml, 0.1 µg/ml, 0.3 µg/ml). 
(B) Cumulative data from 3 independent experiments showing a decrease of procollagen I production in SSc 
fibroblasts incubated with SN38 (0.3 µg/ml). ** p < 0.01 using paired t-test.
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incubation with 0.4 µg/mL SN38 during 24 h significantly increased mRNA expression of CCL2 (+ 163.8 ± 49.6, 
p = 0.04, paired t-test) in dermal fibroblasts of SSc patients treated with SN38 vs. the non-treated condition. No 
difference was noted between SSc patients and HD dermal fibroblasts (data not shown).
These results suggest that irinotecan and its active metabolite SN38 decrease in part the levels of expression 
of some genes mRNA involved in SSc fibrosis.
Discussion
In this study, we showed that both irinotecan, a clinically approved derivative of camptothecin, and its active 
metabolite SN38 significantly inhibit the synthesis of collagen by dermal fibroblasts from patients with diffuse 






































































































































Figure 3.  Analysis of irinotecan effect on mRNA expression of genes involved in fibrosis in dermal SSc 
fibroblasts. Relative mRNA expression of a panel of genes involved in fibrosis (from A to F: COL1A1, COL1A2, 
MMP1, TIMP1, CCL2 and ACTA2) in dermal fibroblasts obtained from 4 systemic sclerosis patients treated 
with irinotecan (20 µg/mL), in comparison to a non-treated condition. The non-treated condition was 
arbitrary fixed at 100%. Analysis of qRT-PCR reactions normalized to stable housekeeping gene GAPDH 
(Glyceraldehyde-3-phosphate dehydrogenase). A level above 100% corresponds to a gene overexpression in 
the treated condition and a level below 100% corresponds to a gene downregulation in the treated condition. 
Mean ± SEM, ns: non significant, * p < 0.05 using paired t-test.
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Fibrosis associated to SSc occurs when inappropriate tissue remodeling leads to excessive ECM deposition, 
predominantly type I collagen by fibroblasts, resulting from abnormal interactions between endothelial cells, 
lymphocytes/monocytes and fibroblasts. In our study we did not observed an increased production of procol-
lagen 1 in SSc fibroblasts when compared to controls (data not shown). To our knowledge, only 2 studies 29,30 
previously showed a potent selective inhibitory effect of camptothecin on collagen synthesis in dermal fibroblasts 
from SSc patients.
The effect of irinotecan and SN38 was assessed on the procollagen I production of dermal fibroblasts of SSc 
patients and HD. A dose-dependent effect was observed, and we thus tested the highest doses (40 µg/ml for 
irinotecan and 0.3 µg/ml for SN38). Our results demonstrated that irinotecan and SN38 significantly inhibits the 
synthesis of procollagen I by dermal fibroblasts from patients with SSc. According to Czuwara-Ladykowska et al. 
































































































































Figure 4.  Analysis of SN38 effect on mRNA expression of genes involved in fibrosis in dermal SSc fibroblasts. 
Relative mRNA expression of a panel of genes involved in fibrosis (from A to F: COL1A1, COL1A2, MMP1, 
TIMP1, CCL2 and ACTA2) in dermal fibroblasts obtained from 4 systemic sclerosis patients treated with SN38 
(0.4 µg/mL), in comparison to a non-treated condition. The non-treated condition was arbitrary fixed at 100%. 
Analysis of qRT-PCR reactions normalized to stable housekeeping gene GAPDH (Glyceraldehyde-3-phsophate 
dehydrogenase). A level above 100% corresponds to a gene overexpression in the treated condition and a level 
below 100% corresponds to a gene downregulation in the treated condition. Mean ± SEM, ns: non significant, 
*p < 0.05, ** p < 0.01, *** p < 0.001 using paired t-test.
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that Irinotecan/SN38 may interact with procollagen production through the same pathway in SSc and non-SSC 
fibroblasts.
The effect of irinotecan and SN38 was then assessed on a panel of 6 key genes involved in ECM remodeling: 
COL1A1 and COL1A2 which are ECM components, MMP1 which is one of the major matrix metalloproteinase 
involved in degradation of the ECM, TIMP1 which is a natural inhibitor of most of the known matrix metal-
loproteinases, CCL2 which is a pro-fibrotic gene coding for an inflammatory chemokine 32 and ACTA2 (alpha-
SMA) which is a pro-fibrotic gene expressed specifically in myofibroblasts. Both incubation with irinotecan and 
SN38 decreased the expression of COL1A1, COL1A2, MMP1 and ACTA2 genes in dermal fibroblasts of HD and 
SSc patients, with a statistically significant effect for SN38. No effect was observed on TIMP1 gene expression. 
Surprisingly, CCL2 gene expression was significantly increased after incubation with SN38. However, the profi-
brotic role of the CCL2/CCR2 axis is controversial. Indeed, CCL2 had no direct effects on collagen production 
by fibroblasts in various studies 33,34. Interestingly, Kalderen et al. 35 demonstrated that CCL2 induces anti-fibrotic 
signaling in fibroblasts independently of CCR2, suggesting that CCL2 may have diametrically opposite effects 
on fibroblasts depending on the in vivo setting in health and disease.
In the field of immunology, in addition to anti-fibrotic effects, immunomodulation of peripheral blood 
mononuclear cells (PBMC) activity could complete the efficacy of irinotecan. In SSc, camptothecin showed 
immunosuppressive activity, down-regulating the expression of IL-2 receptor and then reducing the prolifera-
tion of PBMC and natural killer cells activity 29. Recent publication regarding the interest of irinotecan in murin 
models of Systemic Lupus Erythematosus have suggested that the topo I inhibitor irinotecan is able to suppress 
lupus nephritis in NZB/NZW mice 36, and to suppress both lupus nephritis and lupus-like skin lesions in MRL/
lpr mice 37. Spleen cell populations demonstrated a decrease of approximately one third of the total number of 
B cells as well as lower B and T cell activity in the irinotecan-treated groups. Further experiments showed that 
extremely low concentrations (50 times lower than the dose applied for chemotherapy in humans) of irinotecan 
still suppressed lupus nephritis and prolonged survival in NZB/NZW mice 38. However, B cell activation was 
lower only in the group treated with the highest dose of irinotecan.
In the context of advanced SSc, the safety profile of irinotecan seems acceptable. Indeed, SSc has the highest 
disease-related mortality of all autoimmune connective tissue diseases with a standard mortality ratio of 3.5, a 
median survival time after diagnosis of 11 years, and an absolute survival at 5 years of 77.9%. Cardiopulmonary 
involvement (lung fibrosis, pulmonary arterial hypertension and heart involvement) accounts for the majority of 
the increased mortality in SSc 12. In the recent therapeutic trial evaluating autologous HSCT versus intravenous 
pulse cyclophosphamide in diffuse cutaneous SSc 11, a total of 156 patients were randomly assigned to receive 
HSCT (Hematopoietic stem cell transplantation) (n = 79) or cyclophosphamide (n = 77). During a median follow-
up of 5.8 years, 53 events occurred: 22 in the HSCT group (19 deaths and 3 irreversible organ failures) and 31 
in the control group (23 deaths and 8 irreversible organ failures). This underlines the high level of mortality 
and of morbidity of diffuse scleroderma, whatever the immunosuppressive treatment in a selected population.
Irinotecan is a well-known drug used for more than 12 years in patients with cancer, including patients with 
metastatic cancer in palliative care. In the field of oncology, SN38 is described as 100 to 1000-fold more potent 
as a topo-I inhibitor than irinotecan 39,40, which is consistent with our results. To note, the highest doses we used 
during our experiments (40 µg/ml irinotecan) correspond to the doses currently recommended in oncology (100 
to 350 mg/m2 every week to every third week) and are known to have poor side-effects 41–43, even combined 
with other anticancer drugs such as paclitaxel 44. The adverse events observed in patients treated at the recom-
mended dose were modest and manageable, mainly represented by neutropenia and diarrhea. Regarding these 
data, we hypothesize that the safety profile of irinotecan in SSc patients would be comparable to that of other 
immunosuppressive drugs used in the context of scleroderma such as cyclophosphamide, mycophenolate mofetil, 
or rituximab. Therefore, the benefit/risk ratio of this treatment appears favourable.
Finally, the main limitation of our study is the small number of patients included. Moreover, since irinote-
can and SN38 are topo-I inhibitor, we can not exclude that they may have impact on other protein synthesis 
and that the effect observed may be non-specific. However, regarding the poor prevalence of SSc (7.2–33.9 per 
100,000 individuals in Europe) with high mortality rate (Ten-year survival at 65–73% in Europe) 45 and the lack 
of effective treatment, we believe that our results can be of interest in the field of SSc and deserve further studies.
In conclusion, this study showed that inhibition of Topo-I activity by noncytotoxic doses of irinotecan or its 
active metabolite SN38 could reverse the pro-fibrotic phenotype of fibroblasts from patients with diffuse SSc. 
It paves the road to a potential new treatment for diffuse SSc or other fibrotic diseases with installed fibrosis, 
where effective treatment is still lacking. Further studies will be needed to determine the effect and the safety of 
irinotecan in patients with diffuse SSc.
Data availability
The datasets used and/or analysed during the current study are availablefrom the corresponding author on 
reasonable request.
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